Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Fluorouracil

Fluorouracil
In stock
1% · 5%
from A$47.49
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$56.99A$47.49
A$23.74 per tube

In brief

  • In Australia and most countries fluorouracil (5‑FU) is a prescription medicine (S4); it is supplied via pharmacies, hospitals and specialist clinics as topical creams/solutions or injectable vials — you should not purchase or use it without a prescription and medical supervision.
  • Fluorouracil is an antineoplastic antimetabolite (pyrimidine analogue) used systemically for cancers (colorectal, gastric, breast and others) and topically for actinic keratosis and superficial basal cell carcinoma; it works mainly by inhibiting thymidylate synthase and disrupting DNA synthesis in rapidly dividing cells.
  • Usual doses vary by indication: systemic regimens are protocol‑dependent (example: IV bolus regimens such as 12 mg/kg/day up to 800 mg/day for 4 days then 6 mg/kg every other day in some schedules); topical creams are commonly 0.5–5% applied once or twice daily for 2–6 weeks depending on formulation and lesion.
  • Administration forms include intravenous injection/infusion (vials e.g. 250 mg–1 g or larger) and topical preparations (cream, lotion or solution in 0.5%, 1%, 2%, 4% or 5% strengths) applied to the skin.
  • Onset: topical local effects (erythema, irritation) usually begin within days and lesion response develops over weeks; systemic antitumour effects are seen over treatment cycles (weeks) while systemic side effects may appear within days.
  • Duration of action: topical courses are typically 2–6 weeks or until lesion clearance; systemic cytotoxic effects persist through the chemotherapy cycle (myelosuppression nadir commonly 7–14 days with recovery over ~3–4 weeks) and treatment frequency depends on the chosen protocol.
  • Alcohol warning: avoid heavy alcohol while receiving fluorouracil — alcohol can worsen gastrointestinal effects, affect liver function and healing; follow your prescriber’s advice about alcohol intake during treatment.
  • The most common side effects are local skin reactions with topical use (erythema, burning, pain, desquamation) and systemic effects with IV use such as nausea, vomiting, diarrhoea, stomatitis and myelosuppression.
  • Would you like to try fluorouracil without a prescription?

Basic Fluorouracil Information

  • INN (International Nonproprietary Name): Fluorouracil (also known as 5‑Fluorouracil, 5‑FU).
  • Brand Names Available In Australia: Efudex / Efudex (topical 2% and 5%), generic fluorouracil creams and injection vials (brands vary by supplier).
  • ATC Code: L01BC02 (Antineoplastic agents — Antimetabolites — Pyrimidine analogues).
  • Forms & Dosages: Injection vials commonly 250 mg/5 mL, 500 mg/10 mL and 1 g/20 mL; topical creams 0.5%, 1%, 2%, 4%, 5% in 20–40 g tubes.
  • Manufacturers In Australia: Multiple suppliers and generics supply topical and injectable forms; global manufacturers include Teva, Mylan, Sandoz, Pfizer and Medac (local supplier brands may change).
  • Registration Status In Australia: Registered as a prescription medicine (S4) under Australian regulation.
  • OTC / Rx Classification: Prescription only (Rx); not available over‑the‑counter.

Critical Warnings & Restrictions (Safety First — Australian Context)

Is fluorouracil safe to use without specialist oversight?

Fluorouracil (5‑FU) is a prescription antineoplastic with real teratogenic risk and potential for severe systemic toxicity if misused.

In Australia it is classified S4 (prescription only) and TGA‑regulated prescribing and supply must be followed.

Absolute contraindications include known hypersensitivity to fluorouracil, pregnancy and severe bone‑marrow suppression.

Relative contraindications include severe hepatic or renal impairment, significant cardiac disease and poor nutritional status.

For systemic (IV) use, consider DPYD deficiency testing where available because DPYD variants markedly increase risk of severe toxicity.

Female patients should avoid conception during treatment and follow specialist advice on duration after therapy before attempting pregnancy.

Men should be advised to use effective contraception during and for months after systemic therapy as directed by the treating team.

Emergency signs that require immediate medical review include fever or signs of infection, severe mucositis or mouth pain, severe diarrhoea, uncontrolled vomiting or bleeding.

A checklist Before Starting Treatment:

  • Pregnancy test for women of childbearing potential.
  • Baseline complete blood count (CBC) and liver function tests (LFTs).
  • Renal function tests (eGFR/creatinine) and nutritional assessment.
  • Consider DPYD testing for planned high‑dose systemic regimens where available.
  • Obtain written informed consent with documented counselling per Australian oncology practice.

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Who needs extra monitoring?

Elderly patients do not routinely require automatic dose reduction but need increased monitoring for myelosuppression, dehydration and mucositis due to reduced physiologic reserve.

Pregnancy is a contraindication — fluorouracil is teratogenic (Category D) and should be avoided; topical use may still carry risk and is not recommended in pregnancy.

Severe hepatic or renal impairment alters metabolism and clearance and warrants dose reduction or avoidance depending on specialist advice.

Patients with cardiac disease or poor nutrition have higher morbidity with systemic regimens and need multidisciplinary care.

Monitoring Frequency By Risk Group:

Risk Group CBC LFTs Renal Function
Standard Adult Before treatment, weekly during systemic cycles Baseline, every 1–2 cycles Baseline, every cycle if systemic
Elderly / Comorbid Baseline, weekly or more often per toxicity Baseline, each cycle if abnormalities Baseline, monitor each cycle
Severe Hepatic/Renal Impairment Baseline and more frequent per specialist Baseline and prior to each dose change Baseline and frequent monitoring
  • Pre‑treatment investigations: pregnancy test, CBC, LFTs, renal function, nutrition screen.
  • Follow‑up frequency: tailor to regimen and risk; refer to oncology for dose decisions.
  • Referral prompt: consult a specialist pharmacist or oncologist for dose adjustments in high‑risk patients.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Can treatment affect work or driving?

Systemic fluorouracil can cause fatigue, dizziness, visual disturbance and cognitive effects, which may impair performance in safety‑sensitive roles.

Topical therapy usually causes local reactions and rarely affects driving, but pain or systemic symptoms could be distracting.

Under Australian workplace health and safety laws, counsel patients in safety‑sensitive roles to avoid tasks when symptomatic and to seek a formal fitness‑for‑duty medical if required.

  • Avoid driving, operating heavy machinery or performing safety‑critical tasks if experiencing drowsiness, dizziness, confusion or visual disturbance.
  • Avoid high‑risk jobs temporarily if systemic side effects occur (eg severe fatigue, hypotension from vomiting or diarrhoea).
  • Topical use: avoid tasks only if local pain or systemic symptoms arise.

Side Effect Self‑Monitoring Handout (Short):

  • Check temperature daily; seek urgent review for fever ≥38°C.
  • Stop work and call your oncology team for severe diarrhoea, vomiting, new confusion or fainting.
  • Keep a symptom diary and report changes to your treating clinician promptly.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: Do not drive if you feel drowsy, dizzy, confused or have visual disturbances after systemic 5‑FU.

Topical use is usually compatible with driving unless pain or dizziness occurs.

Follow treating clinician and workplace guidance; consider Austroads medical fitness standards for documentation of fitness for duty.

Usage Basics

What exactly is fluorouracil and how is it supplied?

  1. INN: Fluorouracil (5‑fluorouracil, 5‑FU).
  2. Brand Names: Efudex / Efudex (topical 2% and 5%), various generics, Adrucil (injection internationally).
  3. ATC: L01BC02; listed by WHO as an essential medicine.
  4. Formulation Types: Topical creams (0.5–5%), lotions/solutions and injectable vials for IV use.

Common Strengths And Vial Sizes:

  • Topical creams: 0.5%, 1%, 2%, 4%, 5% in 20–40 g tubes.
  • Injection vials: 250 mg/5 mL, 500 mg/10 mL, 1 g/20 mL (strengths vary by manufacturer).

Note: Confirm TGA‑registered brands and current PBS listings when prescribing or advising on cost.

Legal Classification (TGA‑Approved, PBS‑Listed)

Is fluorouracil covered by the PBS?

Fluorouracil is a TGA‑regulated prescription medicine (S4) in Australia.

PBS subsidy status varies by formulation and indication and can change with negotiated listings and authority requirements.

  • Checklist before advising on cost: verify TGA status, check the PBS Schedule online, confirm authority requirements for subsidy.
  • Community pharmacies commonly dispense topical prescriptions; IV forms are hospital‑supplied.
  • Telehealth e‑prescriptions are acceptable for topical scripts — ensure secure transmission and documentation.

Dosing Guide

How is fluorouracil dosed for skin lesions versus systemic cancer treatment?

Route Typical Dosing Duration Monitoring Needs
Topical (AK, superficial BCC) Apply 1–2× daily based on formulation (0.5–5%) 2–6 weeks depending on lesion and product Local skin checks; advise on skin care and sun avoidance
Systemic (IV) Example protocol: 12 mg/kg/day (max 800 mg/day) IV bolus ×4 days; then 6 mg/kg every other day for six doses (max 400 mg/day) — regimens vary by protocol Per chemotherapy cycle as per oncology protocol CBC, LFTs, renal function before and during cycles; DPYD consideration
  • Checklist For Dose Modifications: consider reductions for severe hepatic impairment, significant renal impairment and substantial toxicity.
  • Topical Counselling Points: apply a thin layer only to the lesion, avoid healthy skin, wash hands after application or wear gloves, protect treated area from sun.

Adjustments For Comorbidities

How are doses changed for liver or kidney problems?

Severe hepatic impairment typically requires dose reduction or avoidance due to reduced metabolism and higher toxicity risk.

Significant renal impairment may require dose adjustment — use clinical judgement and specialist advice.

Elderly patients generally require closer monitoring rather than routine dose change.

Children: safety and dosing require specialist paediatric oncology protocols and are not standard outpatient practice.

  • Comorbidities Prompting Adjustment: severe hepatic disease, severe renal impairment, poor nutrition, active infection.
  • Recommended Monitoring: CBC and LFTs more frequently during systemic therapy; consult an oncology pharmacist for complex adjustments.

Q&A — “What If I Miss A Dose?”

Topical: apply as soon as remembered unless near next scheduled application; do not double up.

IV: contact the oncology team immediately; do not self‑adjust or double dose.

Interaction Chart

Which medicines can increase risk or change response to fluorouracil?

Drug Interaction Clinical Action
Warfarin Potentiation — increased INR and bleeding risk Increase INR monitoring and adjust warfarin dose as needed
Allopurinol Reported increased toxicity with 5‑FU Use caution; monitor for enhanced toxicity
Metronidazole Increased 5‑FU toxicity reported Avoid combination where possible; monitor closely if used
Capecitabine Oral prodrug of 5‑FU — additive toxicity if combined Avoid overlapping therapies unless prescribed by oncology
Herbal Supplements (eg St John’s Wort) Can alter drug metabolism broadly Ask patients to disclose supplements; avoid while on systemic therapy

Clinical actions include medication reconciliation at each visit and tailored monitoring plans.

  • Advise patients to bring all medicines and supplements to every appointment for review.
  • Discuss warfarin management and INR monitoring if on anticoagulation.

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Can food or alcohol change side effects?

Alcohol does not have a direct pharmacokinetic interaction with fluorouracil but may worsen mucositis, GI upset and dehydration during systemic therapy.

Caffeine does not have major interactions but excessive intake can worsen dehydration and sleep disturbance during chemotherapy.

  • Foods/Drinks To Moderate: alcohol, very hot/spicy foods if mucositis is present, highly caffeinated drinks if causing insomnia.
  • Traditional Remedies: ask about herbal teas and supplements; St John’s wort can affect drug metabolism and should be declared.
  • Nutrition Warning Signs: inability to eat, severe vomiting, more than 5% weight loss — refer for urgent dietetic review.

User Reports & Trends (Australian Patient Feedback)

What do Australian patients say about using fluorouracil?

Online patient reviews commonly report topical 5‑FU causing predictable local inflammation, crusting and temporary cosmetic impact but good lesion clearance when used correctly.

Systemic users report classical chemotherapy side effects such as nausea, fatigue, mucositis and hair thinning, consistent with clinical data.

Cost and PBS subsidy expectations are common concerns; patients often compare brands and seek generics from community chains.

  • Patient Sentiments: efficacy balanced against cosmetic reaction for topical use; systemic therapy expected to cause systemic side effects.
  • Counselling Recommendation: prepare patients for the appearance of treated areas, provide written tips for skin care and psychosocial support where needed.

Access & Purchase Options (Australia)

Where can patients obtain fluorouracil in Australia?

Topical fluorouracil is supplied by community and hospital outpatient pharmacies on prescription; IV forms and oncology doses are hospital‑managed.

Pharmacy Type Expected Availability Typical Price Range (Out‑Of‑Pocket) PBS Subsidy Status
Community Chains (Chemist Warehouse, Priceline) Often stock topical brands; can order generics Varies by brand and discounting Conditional — check PBS
Independent Pharmacies May stock or order topical creams Varies Conditional — check PBS
Hospital Pharmacies IV forms and oncology supplies (hospital only) Hospital managed May be PBS‑listed for certain indications
Approved Online Pharmacies Delivery available; confirm e‑script acceptance Varies with delivery fees Conditional — check PBS and supplier

Checklist For Patients Before Travel:

  • Confirm supply quantity and next refill timing.
  • Store creams in a cool place away from heat during travel.
  • Have emergency contact details for treating clinic and local pharmacy.

In our online pharmacy, fluorouracil is available with discreet delivery to Australia in 9–21 days.

Online Pharmacies And Telehealth E‑Prescriptions

Can online services supply fluorouracil safely?

Telehealth can lawfully issue topical 5‑FU prescriptions in Australia; ensure identity verification and secure e‑prescription transmission.

Online pharmacies may deliver topical products, but verify they are TGA‑compliant suppliers and only accept prescriptions from registered clinicians.

  • Steps To Verify A Reputable Online Pharmacy: check for Australian business details, pharmacist contact, and secure prescription handling.
  • For systemic therapy, virtual consults are for follow‑up only; IV administration must occur in hospital or accredited infusion centres.
  • Contact the local pharmacist promptly if delivery is delayed to avoid treatment interruption.

Mechanism & Pharmacology

How does fluorouracil work against abnormal cells?

  • Fluorouracil is a pyrimidine analogue antimetabolite that inhibits thymidylate synthase.
  • It is metabolically activated to nucleotides that incorporate into RNA and DNA, disrupting nucleic acid synthesis in rapidly dividing cells.
  • Topical application achieves high local concentrations with minimal systemic absorption in most cases, making it effective for actinic keratoses and superficial basal cell carcinoma.
  • Systemic IV dosing results in wider distribution and the need for haematological and biochemical monitoring.

Pharmacological Consequences To Counsel Patients About:

  • Mucositis and mouth soreness with systemic therapy.
  • Myelosuppression leading to infection or bleeding risk.
  • Local skin inflammation, desquamation and crusting with topical use.

Clinical Terms Explained (For Patients)

  • Myelosuppression: low blood counts that increase infection and bleeding risk.
  • Mucositis: soreness or ulcers in the mouth and throat.
  • Desquamation: peeling or flaking of the skin at the treatment site.
  • Teratogenicity: the potential to cause harm to an unborn baby.
  • DPYD Deficiency: an inherited enzyme deficiency that raises the risk of severe 5‑FU toxicity; testing may be advised for some systemic regimens.

Indications & Off‑Label Uses

When is fluorouracil used in Australia?

Indication Route Typical Regimen
Actinic Keratosis Topical Apply 1–2× daily for 2–6 weeks depending on formulation
Superficial Basal Cell Carcinoma Topical Tailored topical course, often several weeks
Colorectal, Gastric, Breast Cancers Systemic (IV) Regimens per oncology protocol (eg bolus and cycle dosing)
  • Off‑Label Use: dermatologists may use varying concentrations or durations for specific lesions; always document informed consent for off‑label use.
  • Consent Checklist For Off‑Label Prescribing: explain evidence basis, expected benefits, risks and available alternatives.

Key Clinical Findings (Major Studies 2022–2026)

What recent evidence supports current practice?

  • Topical 5‑FU continues to show reliable clearance of actinic field damage with outcomes comparable to imiquimod and photodynamic therapy in many trials.
  • Systemic 5‑FU remains a backbone agent in combination chemotherapy regimens for colorectal cancer.
  • DPYD genotyping studies reinforce the value of pre‑treatment testing in high‑dose systemic protocols to reduce severe toxicity.
  • Australian real‑world audits highlight adherence challenges for topical regimens driven by local skin reactions and cost barriers when PBS subsidy is not available.
Author Year Finding
Selected Trials (International Reviews) 2022–2026 Topical 5‑FU effective for field treatment of actinic damage; comparable clearance rates to alternatives.
Pharmacogenetics Studies 2022–2026 DPYD variants correlate with increased systemic 5‑FU toxicity; testing recommended in high‑dose protocols.

Alternatives Matrix

What are the main alternative treatments?

Drug Route Typical Use PBS Status
Capecitabine (Xeloda) Oral Oral prodrug alternative for systemic disease Often PBS‑listed for many cancer indications
Imiquimod Topical Alternative for actinic keratosis and superficial BCC Varies by indication
Photodynamic Therapy Procedural Field treatment for actinic damage Not a PBS medication — service cost varies
  • Pros/Cons When Choosing Topical Therapy: consider cost, convenience, cosmetic outcome and side‑effect profile.
  • Discuss PBS subsidy and patient preference when selecting an alternative.

Common Questions (Australian Pharmacy Consultations)

What do patients usually ask at the pharmacy?

  • Q: How long until skin improves? A: Expect local inflammation and crusting; visible healing typically follows completion of the course over weeks.
  • Q: Will the cream stain clothing? A: Creams are usually water‑soluble but can discolour fabrics — avoid contact with clothing until dry.
  • Q: Is it safe in pregnancy or breastfeeding? A: Pregnancy is contraindicated; breastfeeding advice should be sought from the treating clinician.
  • Q: What if I get a fever? A: Fever during systemic therapy requires urgent review for possible neutropenic sepsis.
  • Q: How to avoid mucositis? A: Good oral hygiene and early reporting of mouth soreness helps; anti‑infective strategies as advised by oncology.
  • Q: Are there cheaper generics? A: Ask the pharmacist about generic options and PBS subsidies.
  • Q: Can I use other topical products concurrently? A: Avoid other topical chemotherapeutics unless directed by a dermatologist.
  • Q: What about sunscreen? A: Use sun protection during and after topical treatment as skin is more photosensitive.
  • Q: How to apply the cream? A: Apply a thin layer to lesions only, wash hands afterwards or wear gloves.
  • Q: When to call the clinic? A: For fever, severe diarrhoea, uncontrolled side effects or signs of infection.

Printable Counselling Checklist For Pharmacists: indication, dosing, expected reactions, when to seek urgent care, contraception advice, storage and follow‑up appointments.

Price & Access Comparison Table (Australia)

Pharmacy/Source Typical Price Range (Out‑Of‑Pocket) PBS Subsidy Status Prescription Required Typical Availability Time
Chemist Warehouse Varies by brand; generics often lower Conditional — check PBS Yes In stock or 24–72 hrs
Priceline Varies Conditional — check PBS Yes In stock or 24–72 hrs
TerryWhite Chemmart Varies Conditional — check PBS Yes In stock or 24–72 hrs
Independent Pharmacy Varies Conditional — check PBS Yes May need to order 24–72 hrs
Hospital Pharmacy Hospital managed Depends on indication Yes (hospital use) Hospital only
Approved Online Pharmacy Varies + delivery fee Conditional — check PBS Yes (e‑script) Delivery 9–21 days

Patient Checklist For Cost Conversations: ask about generic options, co‑pay, PBS authority numbers and whether the pharmacy accepts e‑scripts.

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

  • Verify TGA registration of the brand you intend to dispense.
  • Check PBS listing and any authority requirements before advising cost or subsidy.
  • Confirm whether stock is onsite or needs ordering and expected delivery time.
  • For rural patients, advise ordering ahead and carry an extra tube or prescription if travel is imminent.
  • Provide storage advice suitable to Australian climates and a local emergency contact.

Registration & Regulation (TGA & PBS Details)

What regulatory checks should clinicians and pharmacists do?

  • TGA: Australian regulator for medicines — check Product Information and ARTG entry for approved indications and storage instructions.
  • ARTG: Australian Register of Therapeutic Goods for registration details.
  • PBS: Consult the PBS Schedule for current subsidy listings and authority rules.

Regulatory Checklist Before Prescribing/Dispensing:

  • Confirm Product Information and approved formulation strength.
  • Check PBS Schedule and authority requirements where cost subsidy is relevant.
  • Document counselling, consent for off‑label use and any DPYD testing decisions in the medical record.

Storage & Handling (Household And Pharmacy In Australian Climate)

How should fluorouracil be stored at home and in pharmacies?

Product Storage Temperature Notes
Injection Vials 20–25°C Protect from light; do not freeze; follow PI for manufacturer guidance
Topical Creams Below 25°C Protect from moisture and heat; keep tube tightly closed
  • Household Tips: keep creams in a cool cupboard, do not leave in cars or heated bathrooms during hot Australian summers.
  • Pharmacy Handling: maintain ambient storage per Product Information; observe expiry dates and fridge/cold‑chain requirements if specified by manufacturer.
  • Spill/Handling: use gloves when applying or handling topical cream to avoid unintended exposure, especially around pregnant household members.

Guidelines For Proper Use (Pharmacist Counselling & Patient Advice)

What should pharmacists always tell patients?

  • Explain the indication and how to apply topical cream (thin layer, targeted application, avoid healthy skin margins).
  • Describe expected local reaction and that transient worsening may occur before improvement.
  • Advise on contraception and teratogenic risk for systemic therapy and the need for pregnancy testing where relevant.
  • For systemic therapy, emphasise blood test schedules (CBC, LFTs), signs of neutropenic sepsis and antiemetic plans.
  • Provide written information, urgent contact numbers and follow‑up appointment reminders.

Suggested Counselling Checklist Template For Pharmacists:

  • Indication and route of administration.
  • Dosing schedule and what to do if a dose is missed.
  • Common and serious side effects and when to seek urgent care.
  • Drug interactions and medication reconciliation requirement.
  • Storage, handling and contraception advice.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9–14 days
Melbourne Victoria 9–14 days
Brisbane Queensland 9–14 days
Perth Western Australia 9–14 days
Adelaide South Australia 9–14 days
Canberra Australian Capital Territory 9–14 days
Hobart Tasmania 9–14 days
Darwin Northern Territory 14–21 days
Gold Coast Queensland 9–14 days
Newcastle New South Wales 9–14 days
Wollongong New South Wales 9–14 days
Geelong Victoria 9–14 days
Cairns Queensland 14–21 days
Townsville Queensland 14–21 days

Related products